Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens

  • Parrondo J
  • Rincón R
  • Romero G
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Thrombocytopenia limits the use of interferon (INF) based regimens in chronic hepatitis C virus (HCV) patients. Eltrombopag, a thrombopoietin-receptor agonist, effectively elevates platelet count allowing optimal INF-treatment. The objective of the present study was to assess the cost-effectiveness as support treatment in chronic HCV infected patients with thrombocytopenia to enable INF-based treatment regimens from the Spanish Health System perspective. Methods: A two-phase individual-level model was developed to evaluate the cost-effectiveness of eltrombopag treatment in thrombocytopenic HCV-patients over a lifetime horizon. Individual-level models are more flexible and provide more accurate estimations than Markov approaches. One million patients were simulated using data from trials ENABLE 1 and 2 and local studies. In the first phase, a discrete event simulation was used to recreate patient events during INF-treatment. When eltrombopag was considered, patients underwent an initial pre-INF treatment with eltrombopag. Those that failed to reach INF-label platelet count did not receive INF-based regimens. In the second phase, a microsimulation was used to emulate each patient from treatment discontinuation to death. Health states included fibrosis (F0, F1/2, F3, F4), liver decompensation, hepatocelullar carcinoma, liver transplant and death. Transition probabilities for each 1-month cycle, utilities and direct health care costs ( 2014) were obtained from literature and national databases. A 3% annual discount was applied to costs and health outcomes. Sensitivity analysis with 0% and 5% discount rates were performed. Results: Eltrombopag was associated with an average increment of 0.58 quality-adjusted life years (QALY) and an additional cost of 17,084.47/patient. The average incremental cost effectiveness ratio (ICER) was 29,808.26 /QALY. Considering a 30,000 threshold, eltrombopag was cost-effective in 59.12% of cases. This proportion remained similar with 5% (56.7%) and 0% (63.25%) discount rates. Conclusions: With the premises considered in this study, eltrombopag in HCV patients could be considered cost-effective from the Spanish Health System perspective.

Cite

CITATION STYLE

APA

Parrondo, J., Rincón, R. D., Romero, G. M., Sola, L. R., & Roldán, C. (2014). Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens. Value in Health, 17(7), A532. https://doi.org/10.1016/j.jval.2014.08.1692

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free